Evidence map›Paper›PMID 30613263›Full record

ArticleTheranostics2018

miR-200c/141 Regulates Breast Cancer Stem Cell Heterogeneity via Targeting HIPK1/β-Catenin Axis.

Bingjie Liu, Ruikai Du, Lei Zhou, Jiahui Xu, Song Chen, Ji Chen, Xiaoli Yang, Dong-Xu Liu, Zhi-Ming Shao, Lixing Zhang and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
3.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 65 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. MicroRNA-200c in Cancer Generation, Invasion, and Metastasis.International journal of molecular sciences · 2025
    Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Heterogeneity of BCSCs contributes to the metastatic organotropism of breast cancer.Journal of experimental & clinical cancer research : CR · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 3 countries.

Bingjie LiuShanghai Cancer Center & Institutes of Biomedical Sciences, Cancer Institute, Key Laboratory of Breast Cancer in Shanghai, Key Laboratory of Medical Epigenetics and Metabolism, Innovation Center for Cell Signaling Network, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Ruikai DuState Key Laboratory of Space Medicine Fundamentals and Application, China Astronaut Research and Training Center, Beijing, China.
Lei ZhouShanghai Cancer Center & Institutes of Biomedical Sciences, Cancer Institute, Key Laboratory of Breast Cancer in Shanghai, Key Laboratory of Medical Epigenetics and Metabolism, Innovation Center for Cell Signaling Network, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Jiahui XuShanghai Cancer Center & Institutes of Biomedical Sciences, Cancer Institute, Key Laboratory of Breast Cancer in Shanghai, Key Laboratory of Medical Epigenetics and Metabolism, Innovation Center for Cell Signaling Network, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Song ChenInstitute of Medicinal Biotechnology, Jiangsu College of Nursing, Huaian, China.
Ji ChenDepartment of Pathology, Suizhou Affiliated Hospital to Hubei University of Medicine, Suizhou, Hubei, 441300, China.
Xiaoli YangShanghai Cancer Center & Institutes of Biomedical Sciences, Cancer Institute, Key Laboratory of Breast Cancer in Shanghai, Key Laboratory of Medical Epigenetics and Metabolism, Innovation Center for Cell Signaling Network, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Dong-Xu LiuThe Centre for Biomedical and Chemical Sciences, School of Science, Faculty of Health and Environmental Sciences, Auckland University of Technology, Auckland 1010, New Zealand.
Zhi-Ming ShaoShanghai Cancer Center & Institutes of Biomedical Sciences, Cancer Institute, Key Laboratory of Breast Cancer in Shanghai, Key Laboratory of Medical Epigenetics and Metabolism, Innovation Center for Cell Signaling Network, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Lixing ZhangShanghai Cancer Center & Institutes of Biomedical Sciences, Cancer Institute, Key Laboratory of Breast Cancer in Shanghai, Key Laboratory of Medical Epigenetics and Metabolism, Innovation Center for Cell Signaling Network, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Zuoren YuKey Laboratory of Arrhythmias of the Ministry of Education of China, Research Center for Translational Medicine, Translational Medical Center for Stem Cell Therapy, East Hospital, Tongji University School of Medicine, 150 Jimo Road, Shanghai 200120, China.
Ni XieInstitute of translation medicine, Shenzhen Second People's Hospital, The first Affiliated Hospital of Shenzhen University Health Science Center.
Jun-Lin GuanDepartment of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, OH 45267.
Suling LiuShanghai Cancer Center & Institutes of Biomedical Sciences, Cancer Institute, Key Laboratory of Breast Cancer in Shanghai, Key Laboratory of Medical Epigenetics and Metabolism, Innovation Center for Cell Signaling Network, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Fudan University Shanghai Cancer Center · CNAuckland University of Technology · NZChina Astronaut Research and Training Center · CNHubei University of Medicine · CNNanjing Medical University · CNShanghai Medical College of Fudan University · CNShenzhen University Health Science Center · CNTongji University · CNUniversity of Cincinnati Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increasing evidence demonstrates the existence of two inter-convertible states of breast cancer stem cells (BCSCs) with distinct behaviors in proliferation and mobility, and the BCSC heterogeneity is accurately regulated by sophisticated mechanisms including microRNAs. The microRNA-200 family including miR-200c/141 cluster was reported to affect cancer cell invasion and metastasis by regulating epithelial to mesenchymal transition (EMT). However, the effect of miR-200 family on BCSC heterogeneity is uncertain. Thus, we investigated whether the miR-200c/141 cluster had different effects on breast tumor growth and metastasis by switching the two states of BCSC.

Indexed as

Protein Interaction MapsAnimalsbeta CateninBlotting, WesternCarrier ProteinsCD24 AntigenCell MovementCell ProliferationEpithelial-Mesenchymal TransitionGene Expression ProfilingGene Knockout TechniquesIntegrin beta1Mammary Neoplasms, AnimalMiceMicroRNAsNeoplastic Stem Cellsbeta CateninCarrier ProteinsCD24 AntigenCTNNB1 protein, mouseHipk1 protein, mouseIntegrin beta1MicroRNAsMirn141 microRNA, mouseMirn200 microRNA, mouseProtein KinasesProtein Serine-Threonine Kinasesbreast cancercancer stem cellheterogeneityHIPK1miR-200c/141

Identifiers

PMID30613263
PMCPMC6299432
OpenAlexW2902699853

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.